Company intelligence / Profile preview

REZZAYO

San Diego, California, USA

Ownership: Private
Employees: ~80
Development stage: Other

Overview

Cidara Therapeutics is a biotechnology company focused on developing long-acting therapeutics for serious diseases using its proprietary Cloudbreak platform. The company's lead product, REZZAYO (rezafungin), is a once-weekly echinocandin antifungal approved for the treatment of candidemia and invasive candidiasis. Cidara's pipeline also includes drug-Fc conjugates (DFCs) for the prevention and treatment of viral infections like influenza and for various oncology indications. The company has established significant partnerships with Mundipharma and Melinta Therapeutics for the commercialization of rezafungin.

Therapeutic areas: Infectious DiseasesOncology
Modalities: Small moleculePeptidesDrug-Fc conjugate
Industry: Biotech

Partnerships

MundipharmaMelinta TherapeuticsJohnson & Johnson (Janssen)

Beyond the preview

Go deeper on REZZAYO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REZZAYO.

Explore the full profile